Navidea biopharmaceuticals reports third quarter 2022 financial results

Dublin, ohio--( business wire )--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the three-month and nine-month periods ended september 30, 2022.
NAVB Ratings Summary
NAVB Quant Ranking